



Corporate Profile

Fresenius Medical Care

Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 2.1 million individuals worldwide. Through its network of 3,135 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 256,521 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.

Growth Strategy

With GOAL 13...

...new targets of the growth strategy were adopted in September 2010. Thereby we follow up the previous strategy, continuing to pursue the strategic four paths consistently in a financially responsible way to consolidate our position as world market leader in dialysis:

- Organic growth in dialysis services by innovative treatment techniques and the opening of new clinics
- Acquisitions of existing clinics to ensure optimized international presence
- Horizontal expansion in the sector of Renal Drugs as well as
- A boosted activity in home therapies

Key Figures - Summary third quarter 2012

Net revenue	\$ 3,418 million	+ 7%
Operating income (EBIT)	\$ 568 million	+ 6%
Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA	\$ 270 million	- 3%
Earnings per share	\$ 0.88	- 4%
Total assets ¹	\$ 21,860 million	
Operating cash flow ²	\$ 1,467 million	
Employees ¹	85,368	+ 8%
Patients ¹	256,521	+ 12%
Clinics ¹	3,135	+ 9%
Treatments ²	28.6 million	+ 12%

² as of September 30, 2012

³ in the first nine months of 2012


Goals for 2012

Net revenue	~ \$14.0 billion ¹²
Net income	~ \$1.14 billion ¹²
Leverage ratio (Debt/EBITDA)	< 3.0
Capital expenditures	~ \$700 million
Acquisitions	~ \$1.8 billion

¹This does not include the investment gain in the amount of \$140 million in the first nine months 2012 nor does it consider \$70 million after tax

²We define the ~sign as +/- 0-2% deviation from the respective numbers

Revenue third quarter 2012 per region (US\$ 3,418 m)



Management Board

- Dr. Ben J. Lipps (Chairman)
- Rice Powell (Vice Chairman)
- Michael Brosnan
- Roberto Fusté
- Dr. Emanuele Gatti
- Dr. Rainer Runte
- Kent Wanzek

Supervisory Board

- Dr. Gerd Krick (Chairman)
- Dr. Dieter Schenk (Vice Chairman)
- Dr. Walter L. Weisman
- Rolf A. Classon
- William P. Johnston
- Prof. Dr. Bernd Fahrholz



Share Profile – Key Data

Ticker Symbols

Frankfurt Stock Exchange
New York Stock Exchange (NYSE)
Reuters: XETRA / Frankfurt Stock Exchange
Bloomberg

Ordinary shares

FME
FMS
FMEG.DE / FMEG.F
FME GY

Preference shares

FME3
FMS/P
FMEG_p.DE / FMEG_p.F
FME3 GY

Security Identification Numbers

WKN
ISIN
CUSIP No. (NYSE)

578 580	578 583
DE 0005785802	DE 0005785836
358029106	358029205

Financing Instruments and Maturity Profile

	Amount in million	Coupon %	Maturity
Credit Agreement Revolver	~\$ 1,250		October 30, 2017
Credit Agreement Term Loan A	\$ 2,600 ¹		October 30, 2017
Senior Notes 2010 - 2016	€ 250	5.50%	July 15, 2016
Senior Notes 2011 - 2016	€ 100	3-month-Euribor +3.50%	Oct. 15, 2016
Senior Notes 2007 - 2017	\$ 500	6.875%	July 15, 2017
Senior Notes 2011 - 2018	\$ 400	6.50%	September 15, 2018
Senior Notes 2011 - 2018	€ 400	6.50%	September 15, 2018
Senior Notes 2012 - 2019	\$ 800	5.625%	July 31, 2019
Senior Notes 2012 - 2019	€ 250	5.25%	July 31, 2019
Senior Notes 2011 - 2021	\$ 650	5.75%	February 15, 2021
Senior Notes 2011 - 2021	€ 300	5.25%	February 15, 2021
Senior Notes 2012 - 2022	\$ 700	5.875%	January 31, 2022
Notes (Schuldscheindarlehen) 2009 - 2014	€ 45 ¹		October 27, 2014
Accounts Receivable Facility	\$ 800		July 31, 2014

¹ at the beginning before amortisation

Share Price Development last 12 months

in €




Financial Calendar

Event	Date
Report on Third Quarter 2012:	
Quarterly Financial Report:	November 30, 2012
Report on Full Year 2012:	February 26, 2013
Report on First Quarter 2013:	April 30, 2013
Annual General Meeting 2013:	May 16, 2013
Report on Second Quarter 2013:	July 30, 2013
Report on Third Quarter 2013:	November 5, 2013

Capital Structure

Overview



Contacts

Fresenius Medical Care AG & Co. KGaA
 Investor Relations & Corporate Communications
 Else-Kröner-Straße 1 61352 Bad Homburg

Oliver Maier P: +49(0)6172-609-2525
 Senior Vice President, F: +49(0)6172-609-2301
 Head of IR & CC

Gerrit Jost P: +49(0)6172-609-5216
 Vice President

North America
Terry L. Morris P: +1-800-948-2538
 Vice President F: +1-615-345-5605